Alantra advises the shareholders of global beauty business Pangaea on its investment from Inflexion

Mar 2021

Sell-side advisory

London – Alantra, the independent global mid-market investment bank, has advised the shareholders of Pangaea Laboratories (“Pangaea”), a global beauty business and owner of the fast-growing Medik8 skincare brand, on its investment from Inflexion.

Founder-led since 1999, Pangaea is an innovative and fully vertically integrated firm with two facilities in Hertfordshire, UK where Medik8’s products are developed and manufactured in-house.

Medik8 is a premium skincare brand focused on science-based, skin-ageing products. With a strong heritage in the international professional channel and a growing online presence, Medik8 is committed to ethical manufacturing and sustainability. Medik8 is focused on enhancing its strong relationships within the professional beauty industry while growing digital channels in new international markets.

Medik8’s expertise has enabled them to develop a range of high performance skincare products focused on Vitamin C, Sunscreen and Vitamin A, their “CSA” philosophy. The business has successfully built its own ecommerce channel and relationships with premium beauty e-tailers to market directly to consumers, who have become better educated around skincare ingredients and efficacy.

The brand has proven its relevance across important international territories, and is now well placed to continue its high rate of growth, particularly in North America.

The Alantra team comprised Matthew Wiseman, Chris Bates, Oliver Hickley and Saro Djerrahian. Matthew Wiseman, partner at Alantra, said: “We’re thrilled to have delivered an exceptional result for such a first-class team and brand. Inflexion will be a great partner for Medik8, and their investment will allow Management to continue to invest in innovation, capitalise on the growth potential in both the ecommerce and professional channels, and continue its global growth.“